Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus capecitabine as adjuvant therapy for high‑risk extrahepatic cholangiocarcinoma
ChiCTR2400081048Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and capecitabine in extrahepatic cholangiocarcinoma (eCCA), sponsored by Chongqing University Cancer Hospital. Primary endpoint: 2-year recurrence-free survival rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tislelizumabcapecitabine
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on ChiCTR2400081048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081048.